United Therapeutics Corporation (UTHR)

United Therapeutics Revenue by Segment

Period Ending	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Tyvaso	1.88B	1.83B	1.79B	1.71B	1.62B	1.56B	1.45B	1.37B
Tyvaso Growth	15.91%	17.66%	23.39%	25.33%	31.34%	38.18%	36.87%	45.60%
Remodulin	526.80M	533.30M	535.70M	548.30M	538.10M	518.70M	521.50M	501.40M
Remodulin Growth	-2.10%	2.81%	2.72%	9.35%	8.75%	3.29%	7.50%	2.35%
Orenitram	496.90M	483.50M	465.60M	448.80M	434.30M	410.60M	389.40M	377.40M
Orenitram Growth	14.41%	17.75%	19.57%	18.92%	20.84%	16.95%	12.35%	14.19%
Unituxin	226.80M	232.00M	245.20M	238.50M	238.70M	225.40M	215.60M	208.20M
Unituxin Growth	-4.99%	2.93%	13.73%	14.55%	20.01%	24.26%	22.36%	18.03%
Adcirca	30.00M	26.90M	24.20M	23.40M	23.80M	25.90M	26.20M	28.00M
Adcirca Growth	26.05%	3.86%	-7.63%	-16.43%	-17.65%	-20.31%	-27.02%	-27.84%
Other	24.00M	22.90M	21.50M	20.90M	22.10M	20.50M	16.90M	14.50M			-	-	-	-	-	-	-	-	-	-	-	-
Other Growth	8.60%	11.71%	27.22%	44.14%	82.64%	12.64%	-	-			-	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

Period Ending	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
United States	3.04B	2.99B	2.93B	2.85B	2.74B	2.62B	2.49B	2.37B
United States Growth	10.85%	14.12%	17.90%	19.96%	24.41%	25.96%	24.63%	26.68%
International	145.70M	138.50M	145.40M	146.30M	137.70M	136.30M	129.50M	124.30M
International Growth	5.81%	1.61%	12.28%	17.70%	9.90%	9.65%	12.32%	15.84%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.